PFE 241220 25.50P (PFE241220P25500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

PFE241220P25500

Watchlist

0.63
+0.14+28.57%

15min DelayClose Dec 16 16:00 ET

0.64High0.38Low

Intraday

5D
Daily

News

Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $27
Moomoo News20:31 ET · Ratings
Pfizer (PFE) Gets a Hold From Wells Fargo
TipRanks19:59 ET · Ratings
Pfizer Options Spot-On: On December 16th, 205.72K Contracts Were Traded, With 3.69 Million Open Interest
Moomoo News16:30 ET
Sangamo Surges 24% After Roche Ends Development of Hemophilia A Gene Therapy
Seeking Alpha14:58 ET
Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs. -- Barrons.com
Barron's14:03 ET
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Benzinga13:53 ET

Comments

10xStockPicks

Yesterday 08:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Yesterday 05:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

Phil Dunn

Dec 14 10:48

Weekly Trading Report (2nd Week Dec)

A quick update of my trading activities in this week (9 to 13 Dec 2024).
New Positions
$Symbotic (SYM.US)$ , $IonQ Inc (IONQ.US)$ , $Alphabet-A (GOOGL.US)$ , $PepsiCo (PEP.US)$ , $Futu Holdings Ltd (FUTU.US)$
Sold out Positions
$Hershey (HSY.US)$ , $UnitedHealth (UNH.US)$ , $Taiwan Semiconductor (TSM.US)$
Increased / Decreased Positions
None
Remarks
- I sold out $Hershey (HSY.US)$ after buyout news came out. I took decent profit from this rumour.
- Just few days after I bought $UnitedHealth (UNH.US)$ , I sold ...

2024 recap: Relive your key investment moments

Deep Sea

Dec 12 17:31

$Pfizer (PFE.US)$
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer.
"Our decision to increase our quarterly dividend underscores our strong fi...

Moomoo Recap US

Dec 11 15:29

Columns Nasdaq Surges Past 20,000 for the First Time, Powered by Tech Giants | Wall Street Today

The $Nasdaq Composite Index (.IXIC.US)$ hit a record intraday and closing high Wednesday, crossing 20,000 points for the first time. The index was up 1.8% at 20,050 in late trading, finishing 1.77% higher. The $S&P 500 Index (.SPX.US)$ closed just below its highest close on record at 6,090.27, while the $Dow Jones Industrial Average (.DJI.US)$ fell 0.2%.
MACRO
In economic news, November’s consumer price index (C...

Weekly Buzz